Strategy analysis

Pharma-Payer Partnerships in Emerging Markets

Payer partnerships are becoming widespread as emerging markets become wealthier, but access challenges remain. Partnerships with proven success include “strategic philanthropy,” patient access programs, tiered pricing, and service support models.

July 26, 2017

Pharma’s Patient Centricity

Patient centricity is the buzzword of this decade, and necessarily so: it either underpins, or is an inevitable result of, all the forces shaping today’s rapidly evolving healthcare landscape.

October 17, 2016

Pneumococcal Vaccines KOL Interview

Datamonitor interviewed three infectious diseases specialists to determine the physicians’ views on marketed and pipeline pneumococcal vaccines. Two physicians were based in Chicago, IL and one in the UK. The three interviews were combined into a single report.

August 27, 2016

Poland Pricing and Reimbursement

The average drug price in Poland is the lowest in the EU, mainly due to the high proportion of generic pharmaceuticals, low availability of innovative drugs, and high price pressure on reimbursed drugs.

November 4, 2016

Post-AAIC KOL Interview

Crenezumab data was negative in a Phase II study in mild to moderate AD. The signal in not pre-specified isn’t convincing. These data likely will have ethical implications for the asymptomatic, genetic AD predisposition study in the Columbian trial.

August 6, 2014

Post-AASLD US KOL Interview

Over 95% SVR for easy-to-treat patients, and it’s one pill a day for 8-12 weeks for most. In that context, the only way you can improve up on that is to improve care for all populations, not just for easy-to-treat but the difficult-to-treat: decompensated cirrhotics, the post-transplant, and HIV co-infected patients.

December 16, 2014

Post-ADPD Alzheimer’s Disease KOL Interview

Key Highlights BIIB-037 Amyloid beta PET data show positive Abeta reduction; cognitive results are not interpretable with such small numbers. (BIIB) BIIB-037 Phase Ib result interpretation may be effected by the ApoE4 dropouts in the treatment arm. (BIIB) MK-8931 and BIIB-037 show sufficient target engagement, but there is no evidence to date that amyloid clearance […]

April 8, 2015

Post-CHDI Huntington’s Disease KOL Interview

$799.00

Indications: Huntington’s Disease, Alzheimer’s Disease Physician Information Specialty: Neurology Location: London, United Kingdom

March 16, 2015

Post-Clinical Trials on Alzheimer’s Disease (CTAD) 2016 Survey

Biomedtracker conducted a 5-question survey of 51 United States and 47 European (from France, Germany, Italy, Spain and United Kingdom) neurologists who currently treat patients in all stages of Alzheimer’s disease and who followed data presented at Clinical Trials on Alzheimer’s Disease (CTAD) 2016 to gauge their views on the pipeline anti-amyloid beta monoclonal antibodies solanezumab (LLY) and aducanumab (BIIB) and projected use of these potentially disease-modifying drugs if FDA-approved.

March 9, 2017

Post-EASL KOL Insight Interview

The European Association for the Study of the Liver (EASL) held the 2014 International Liver Meeting in
London from April 9-13. The main focus of this year’s meeting was the clinical use of currently approved and
soon-to-be approved, direct-acting antivirals for Hepatitis C.

May 6, 2014

Post-EASL KOL Interview

Highlights KOL believes elsbasvir and grazoprevir data will lead to approval and look similar to available drugs on the market (MRK). Post-liver transplant data for sofosbuvir and simpeprevir was positive (GLD, JNJ). Three DAA combination of -5816,-9857, and sofosbuvir looked good, but most physicians are erring on the side of conservative 12- week treatment regimens […]

May 29, 2015

Precision Medicine and the Future of Healthcare

Precision medicine is typically associated with the use of therapies that target particular disease-linked genetic mutations, identified via a diagnostic test.

October 14, 2016

Product Launch and Commercialization Strategies

Recent years have seen changes in the marketplace that have made successful new drug launches difficult to achieve. Many therapy areas are becoming hypercompetitive, with similar treatments jostling for position, and even those products with evidence of superior efficacy or better tolerability still have to overcome reimbursement hurdles.

December 12, 2016

Profitability Assessment of Branded Generic Inhalers

We set out to examine the extent to which order of market entry influences the prospects of achieving a satisfactory return on investment for companies developing branded generic and generic inhaled products.

October 31, 2016